Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions - PubMed (original) (raw)
Clinical Trial
. 2001 Jul-Aug;21(4B):2895-900.
C H Hsu, J K Lin, M M Hsu, Y F Ho, T S Shen, J Y Ko, J T Lin, B R Lin, W Ming-Shiang, H S Yu, S H Jee, G S Chen, T M Chen, C A Chen, M K Lai, Y S Pu, M H Pan, Y J Wang, C C Tsai, C Y Hsieh
Affiliations
- PMID: 11712783
Clinical Trial
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
A L Cheng et al. Anticancer Res. 2001 Jul-Aug.
Abstract
Curcumin (diferuloylmethane), a yellow substance from the root of the plant Curcuma longa Linn., has been demonstrated to inhibit carcinogenesis of murine skin, stomach, intestine and liver. However, the toxicology, pharmacokinetics and biologically effective dose of curcumin in humans have not been reported. This prospective phase-I study evaluated these issues of curcumin in patients with one of the following five high-risk conditions: 1) recently resected urinary bladder cancer; 2) arsenic Bowen's disease of the skin; 3) uterine cervical intraepithelial neoplasm (CIN); 4) oral leucoplakia; and 5) intestinal metaplasia of the stomach. Curcumin was taken orally for 3 months. Biopsy of the lesion sites was done immediately before and 3 months after starting curcumin treament. The starting dose was 500 mg/day. If no toxicity > or = grade II was noted in at least 3 successive patients, the dose was then escalated to another level in the order of 1,000, 2,000, 4,000, 8,000, and 12,000 mg/day. The concentration of curcumin in serum and urine was determined by high pressure liquid chromatography (HPLC). A total of 25 patients were enrolled in this study. There was no treatment-related toxicity up to 8,000 mg/day. Beyond 8,000 mg/day, the bulky volume of the drug was unacceptable to the patients. The serum concentration of curcumin usually peaked at 1 to 2 hours after oral intake of crucumin and gradually declined within 12 hours. The average peak serum concentrations after taking 4,000 mg, 6,000 mg and 8,000 mg of curcumin were 0.51 +/- 0.11 microM, 0.63 +/- 0.06 microM and 1.77 +/- 1.87 microM, respectively. Urinary excretion of curcumin was undetectable. One of 4 patients with CIN and 1 of 7 patients with oral leucoplakia proceeded to develop frank malignancies in spite of curcumin treatment. In contrast, histologic improvement of precancerous lesions was seen in 1 out of 2 patients with recently resected bladder cancer, 2 out of 7 patients of oral leucoplakia, 1 out of 6 patients of intestinal metaplasia of the stomach, I out of 4 patients with CIN and 2 out of 6 patients with Bowen's disease. In conclusion, this study demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months. Our results also suggest a biologic effect of curcumin in the chemoprevention of cancer.
Similar articles
- Treatment of arsenical keratosis and Bowen's disease with acitretin.
Yerebakan O, Ermis O, Yilmaz E, Basaran E. Yerebakan O, et al. Int J Dermatol. 2002 Feb;41(2):84-7. doi: 10.1046/j.1365-4362.2002.01372.x. Int J Dermatol. 2002. PMID: 11982642 - Arsenic-induced keratoses and Bowen's disease.
Watson K, Creamer D. Watson K, et al. Clin Exp Dermatol. 2004 Jan;29(1):46-8. doi: 10.1111/j.1365-2230.2004.01447.x. Clin Exp Dermatol. 2004. PMID: 14723721 - Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy.
Karrer S, Szeimies RM, Hohenleutner U, Landthaler M. Karrer S, et al. Am J Clin Dermatol. 2001;2(4):229-37. doi: 10.2165/00128071-200102040-00004. Am J Clin Dermatol. 2001. PMID: 11705250 Review. - Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source.
Varma S, Wilson H, Kurwa HA, Gambles B, Charman C, Pearse AD, Taylor D, Anstey AV. Varma S, et al. Br J Dermatol. 2001 Mar;144(3):567-74. doi: 10.1046/j.1365-2133.2001.04085.x. Br J Dermatol. 2001. PMID: 11260016 Review.
Cited by
- Curcumin Ameliorates Heat-Induced Injury through NADPH Oxidase-Dependent Redox Signaling and Mitochondrial Preservation in C2C12 Myoblasts and Mouse Skeletal Muscle.
Yu T, Dohl J, Wang L, Chen Y, Gasier HG, Deuster PA. Yu T, et al. J Nutr. 2020 Sep 1;150(9):2257-2267. doi: 10.1093/jn/nxaa201. J Nutr. 2020. PMID: 32692359 Free PMC article. - Herbal and plant therapy in patients with inflammatory bowel disease.
Triantafyllidi A, Xanthos T, Papalois A, Triantafillidis JK. Triantafyllidi A, et al. Ann Gastroenterol. 2015 Apr-Jun;28(2):210-220. Ann Gastroenterol. 2015. PMID: 25830661 Free PMC article. Review. - Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence.
Kotecha R, Takami A, Espinoza JL. Kotecha R, et al. Oncotarget. 2016 Aug 9;7(32):52517-52529. doi: 10.18632/oncotarget.9593. Oncotarget. 2016. PMID: 27232756 Free PMC article. Review. - Biological Potential and Bioaccessibility of Encapsulated Curcumin into Cetyltrimethylammonium Bromide Modified Cellulose Nanocrystals.
Casanova F, Pereira CF, Ribeiro AB, Castro PM, Freixo R, Martins E, Tavares-Valente D, Fernandes JC, Pintado ME, Ramos ÓL. Casanova F, et al. Pharmaceuticals (Basel). 2023 Dec 17;16(12):1737. doi: 10.3390/ph16121737. Pharmaceuticals (Basel). 2023. PMID: 38139863 Free PMC article. - The Curcumin Analogue 1,5-Bis(2-hydroxyphenyl)-1,4-pentadiene-3-one Induces Apoptosis and Downregulates E6 and E7 Oncogene Expression in HPV16 and HPV18-Infected Cervical Cancer Cells.
Paulraj F, Abas F, Lajis NH, Othman I, Hassan SS, Naidu R. Paulraj F, et al. Molecules. 2015 Jun 29;20(7):11830-60. doi: 10.3390/molecules200711830. Molecules. 2015. PMID: 26132907 Free PMC article.